---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-26-000038"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:28:55.883496+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions closes $150M Term Loan with OrbiMed, extends maturities, cuts interest expense 200 bps

## Summary
- New $150M Term Loan with OrbiMed matures April 2031, replaces prior $150M OHA facility; ABL reduced to $50M.
- Interest expense on Term Loan reduced by 200 basis points annually (Term SOFR + 6.25%, floor 3%).
- Delayed draw term loan of $75M available for 24 months for acquisitions/growth capex.
- Maturities extended to April 2031 from August 2029 (Term Loan) and Sept 2029 (ABL).
- Company expects lower interest expense and enhanced flexibility to support transformation plan.

## SEC filing metadata
- accession: 0001367644-26-000038
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 3.02, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/0001367644-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/ebs-20260416.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-26-000038
- JSON: https://secwatch.observer/filing/0001367644-26-000038.json
- Plain text: https://secwatch.observer/filing/0001367644-26-000038.txt

## Source-grounded claims
- claim_id: fe09344dad4ce3cd5c0d64f15a1c6e6495d2794b
  claim: Emergent BioSolutions Inc. incurred term loan of $150 million with OrbiMed Royalty & Credit Opportunities V, LP at Term SOFR (subject to a floor of 3.00%) plus 6.25% per annum maturing April 16, 2031.
  evidence_excerpt: The Term Loan Agreement provides for (i) a term loan (the “Initial Term Loan”) in an aggregate principal amount equal to $150 million, which was drawn in full on the date of entry into the Term Loan Agreement (the “Closing Date”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/0001367644-26-000038-index.htm
- claim_id: 8154ff82b7561e31920c4bfe671756d9531835b6
  claim: Emergent BioSolutions Inc. entered into Term Loan Agreement with OrbiMed Royalty & Credit Opportunities V, LP valued at $150 million (effective 2026-04-16).
  evidence_excerpt: On April 16, 2026, Emergent BioSolutions Inc. (the “Company”) entered into a Credit Agreement (the “Term Loan Agreement”) by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/0001367644-26-000038-index.htm
- claim_id: a96585b7909aed6902767fe8e3ae1006c64a9f8c
  claim: Emergent BioSolutions Inc. terminated Prior Credit Agreement with OHA Agency LLC.
  evidence_excerpt: repay all amounts outstanding and terminate commitments under the Credit Agreement dated as of August 30, 2024, by and among the Company, the lenders from time to time party thereto and OHA Agency LLC as administrative agent (as amended, the "Prior Credit Agreement")
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764426000038/0001367644-26-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.